Research Article| Volume 10, ISSUE 3, P201-213, October 1988

New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women

      This paper is only available as a PDF. To read, Please Download here.


      Fifty (50) healthy ovulating women aged between 35 and 47 yr (mean age 39) were randomly allocated to one of two groups treated with biphasic formulations of either oestradiol valerate/cyproterone acetate (Group A) or oestradiol valerate/norethisterone (Group B). A double-blind design was used during the first 6 mth of treatment. In Group A, 21 out of 26 women (81%), and in Group B, 16 out of 24 (67%) completed the first year of treatment. No pregnancies occurred.
      The mid-cycle serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) peaks were suppressed, but there were no differences between the pretreatment serum oestradiol values and those observed during the treatment cycles. The serum progesterone values indicated that only one ovulatory cycle occurred during the first year in Group A, while there were 11 in Group B. Ultrasonic studies revealed follicular growth during treatment in both groups, most follicles becoming atretic or persistent without ovulation.
      No significant changes were observed in 11 coagulation factors studied in 16 women in Group A. Serum total cholesterol decreased by about 10% in both groups.
      In Group A bleeding became scantier and dysmenorrhoea disappeared. The incidence of spotting varied between 30% and 40%, but it is important to note that the total number of bleeding days per cycle fell.
      The oestradiol valerate/cyproterone acetate combination was thus found to inhibit ovulation, provide tolerable cycle control and to be free from adverse metabolic side effects.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Royal College of General Practitioners
        Oral Contraception, Study: Further analysis of mortality in oral contraceptive users.
        Lancet. 1981; 1: 541-546
        • Oxford Family Planning Association contraceptive study
        Oral contraceptives and venous thromboembolism: findings in a large prospective study.
        Br Med J. 1986; 292: 526
        • Meade TW
        • Greenberg G
        • Thompson SG
        Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg preparations.
        Br Med J. 1980; 280: 1157-1161
        • Gray HR
        Biological and social interaction in the determination of late fertility.
        J Biosoc Sci. 1979; : S97-115
        • Guillebaud J
        Contraception for the older woman.
        J Obstet Gynaecol. 1985; 5: 70-77
        • Åstedt B
        • Svanberg L
        • Jeppsson S
        • Lideholm P
        • Rannevik G
        The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives.
        Br Med J. 1977; i: 269
        • Serup J
        • Bostofte E
        • Larsen S
        • Westergaard J
        Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with gestagen.
        Acta Obstet Gynecol Scand. 1981; 60: 203-206
        • Neumann E
        Experimental basis for the clinical use of antiandrogens.
        in: Bruchovsky N Chapdelaine A Neumann F Regulation of androgen action. Congressdruck R. Brückner, Berlin1984: 43-49
        • Laurell CB
        Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.
        Anal Biochem. 1966; 15: 45-52
        • Owren PA
        Quantitative one-stage method for assay of prothrombin.
        J Clin Lab Invest. 1949; 1: 81-83
        • Denson KW
        The specific assay of Prower-Stuart factor and factor VII.
        Acta Haematol. 1961; 25: 105-120
        • Lähteenmäki P
        • Rasi V
        • Luukkainen T
        • Myllylä G
        Coagulation factors in women using oral contraception or intrauterine devices after abortion.
        Am J Obstet Gynecol. 1981; 141: 175-179
        • Rasi V
        • Ikkala E
        • Torstila I
        Plasma beta-thromboglobulin in acute myocardial infarction.
        Thromb Res. 1982; 25: 203-212
        • Viikari J
        Precipitation of plasma lipoproteins by BEG-6000 and its evaluation with electrophoresis and ultracentrifugation.
        Scand J Lab Invest. 1976; 36: 265-268
        • Hammond GL
        • Lähteenmäki P
        A versatile method for determination of serum cortisol binding globulin and sex hormone binding globulin binding capacities.
        Clin Chim Acta. 1983; 132: 101-110
        • Humpel M
        • Wendt H
        • Dogs G
        • Weiss ChR
        • Reitz S
        • Speck U
        Intraindividual comparison of pharmacokinetic parameters of d-norgestrel, lynestrenol and cyproterone acetate in 6 women.
        Contraception. 1977; 16: 199-202
        • Ylikorkala O
        • Dawood MY
        New concept in dysmenorrhea.
        Am J Obstet Gynecol. 1978; 130: 833-847
        • Van der Vange N
        • Bruise HW
        • Tweel IVD
        Ovarian activity and oral contraceptives.
        Adv Contraception. 1985; 3: 24
        • Yen SSC
        • Martin P
        • Burnier A
        • et al.
        Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17β-estradiol in post-menopausal women.
        J Clin Endocrinol Metab. 1975; 40: 518-522
        • Hirvonen E
        Progestins: How effective? How safe?.
        in: Newton M Proceedings Xth World Congress of Gynecology and Obstetrics. Academic Professional Information Services, San Francisco1982: 243-251
        • Böttiger LE
        • Boman G
        • Eklund G
        • Westerholm B
        Oral contraceptives and thromboembolic disease: effects of lowering oestrogenic content.
        Lancet. 1980; i: 1098-2101